Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2430460 | 0.99 | IRAK4 (0.39) | IRAK4PIM1 | |
| SCHEMBL4565059 | 0.92 | IRAK4 (0.37) | IRAK4 | |
| Hydrochloric Acid SCHEMBL2743685 | 0.91 | IRAK4 (0.39) | IRAK4 | |
| Hydrochloric Acid SCHEMBL1071140 | 0.90 | IRAK4 (0.39) | IRAK4 | |
| SCHEMBL15213329 | 0.86 | IRAK4 (0.40) | IRAK4PIM1 | |
| SCHEMBL6913962 | 0.84 | PIM1 (0.39) | IRAK4PIM1 | |
| SCHEMBL4756377 | 0.84 | PIM1 (0.39) | IRAK4PIM1 | |
| SCHEMBL1062366 | 0.84 | PIM1 (0.39) | IRAK4PIM1 | |
| SCHEMBL12963791 | 0.84 | IRAK4 (0.38) | IRAK4 | |
| Hydrochloric Acid SCHEMBL3360571 | 0.83 | PIM1 (0.39) | IRAK4PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2816054-A1 | MACROCYCLIC COMPOUNDS FOR SUPPRESSING REPLICATION OF HEPATITIS C VIRUS | GINKGO PHARMA CO., LTD. (CN) | 2014-12-24 | — | — | EP | disclosed |
| WO-2013120371-A1 | MACROCYCLIC COMPOUNDS FOR SUPPRESSING REPLICATION OF HEPATITIS C VIRUS | 银杏树药业(苏州)有限公司 (CN) | 2013-08-22 | — | — | WO | disclosed |
| US-8314062-B2 | Macrocyclic compounds as antiviral agents | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2012-11-20 | — | — | US | disclosed |
| US-8314062-B2 | Macrocyclic compounds as antiviral agents | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2012-11-20 | — | — | US | disclosed |
| US-20090312241-A1 | Macrocyclic Compounds as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-12-17 | — | — | US | disclosed |
| US-20090312241-A1 | Macrocyclic Compounds as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-12-17 | — | — | US | disclosed |
| WO-2007148135-A1 | MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312241-A1 | Macrocyclic Compounds as Antiviral Agents | ZC3HAV1, ZC3HAV1L, HAVCR2 | IRAK4 1025/4885PIM1 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.